Evidence before claims
State what is known, what is inferred, what remains uncertain, and what evidence would change the decision.
About Axiom
A development partner for complex cell-therapeutics programs
Axiom brings scientific, operational, training, and quality-system thinking together so teams can make better development decisions.
Our purpose
Turn a promising concept into a controlled, testable development program.
Cell therapeutics sit at the intersection of biology, manufacturing, quality, nonclinical evidence, clinical medicine, and regulation. Decisions in one area quickly change the risks and requirements in every other area.
Axiom’s role is to help research and development teams frame those decisions, build traceable evidence, prepare people and systems, and communicate limitations clearly.
Working principles
What should remain true as a program grows
Product before platform
Control the specific product, process, assay, route, dose, and indication rather than relying on a broad platform label.
Quality by stage and risk
Build controls that are appropriate to the development stage and product risk, while protecting future comparability and traceability.
Patients are not marketing proof
Do not convert anecdotes, mechanistic hope, registry listings, or early signals into claims of safety or effectiveness.
Document the decision
Record assumptions, owners, evidence, alternatives, acceptance criteria, and the reason for each material development choice.
Escalate the unknown
Bring unresolved medical, regulatory, legal, statistical, and quality questions to qualified specialists at the right time.